NOTE 4 - CAPITAL STOCK | Capitalization The authorized capital of the Company is 500,000,000 shares of capital stock, divided into 480,000,000 shares of common stock with a par value of $0.001 per share, and 20,000,000 shares of preferred stock with a par value of $0.001 per share. Prior to an amendment on November 24, 2014, capitalization was 100,000,000 shares of common stock with a par value of $0.00001 The Company reserved 10,000,000 shares of common stock for issuance under its 2016 Omnibus Equity Incentive Plan. No preferred shares have been issued to December 31, 2018 or to the date of issue of these financial statements. Shares On December 3, 2018, the Company issued 1,478,140 common shares in exchange for debt totaling $48,778 owed to a related party, comprised of $40,205 in loans and $8,573 in accrued interest. During the year ended December 31, 2017, the Company did not issue any shares of its common stock. Options On November 20, 2018, the Company granted 500,000 non-qualified stock options pursuant to the Equity Incentive Plan, to key outside consultants, with 50% vesting after one year and 50% vesting after two years. Each option is exercisable into one share of the Company’s common stock at a price of $0.06 per share, for a term of five years. The options had an estimated grant date fair value of $10,408. For the year ended December 31, 2018, $1,340 (2017 - $Nil) was included in consulting services expense, based on fair value estimates determined using the Black-Scholes option pricing model with an average risk-free rate of 2.51%, a weighted average life of 4.89 years, volatility of 190.47%, and dividend yield of 0%. The valuation used average weekly pricing. At December 31, 2018, the options had an intrinsic value of $0 ($2017 - $0) based on the exercise price of $0.06 per option and a market price of $0.022 per share. On February 14, 2017, the Company granted 9,500,000 non-qualified stock options pursuant to the Equity Incentive Plan, to key corporate officers and outside consultants, with 25% vesting immediately and a further 25% vesting every six months thereafter for eighteen months. Each option is exercisable into one share of the Company’s common stock at a price of $0.06 per share, equal to the closing price of the common stock on the grant date, for a term of five years. The options had an estimated grant date fair value of $536,750. For the year ended December 31, 2018, $56,572 (2017 - $442,808) was included in consulting services expense, based on fair value estimates determined using the Black-Scholes option pricing model with an average risk-free rate of 1.98%, a weighted average life of 4.837 years, volatility of 189.07%, and dividend yield of 0%. The valuation used average weekly pricing. At December 31, 2018, the options had an intrinsic value of $0 ($2017 - $0) based on the exercise price of $0.06 per option and a market price of $0.022 per share. A summary of option activity in the current year and options outstanding at December 31, 2018 is as follows: Options Exercise Price Weighted Average Exercise Price Weighted Average Life Remaining (Years) Expiry Date Intrinsic Value Issued Vested Balance December 31, 2017 9,500,000 4,750,000 $0.06 $0.06 4.12 February 14, 2022 - Issued 500,000 - $0.06 $0.06 4.89 November 20, 2023 - Expired - - - - - - - Exercised - - - - - - - Balance December 31, 2018 10,000,000 9,500,000 $0.06 $0.06 3.21 - Warrants During the years ended December 31, 2018 and 2017, no warrants to purchase shares of common stock were issued and no warrants were exercised. At December 31, 2018, warrants issued in 2015 had an intrinsic value of $6,672 (2017 - $40,033) based on the exercise price of $0.02 per warrant and a market price of $0.022 per share. A summary of warrant activity in the current year and warrants outstanding at December 31, 2018 is as follows: Number of Warrants Exercise Price Weighted Average Exercise Price Weighted Average Life Remaining (Years) Expiry Date Intrinsic Value Balance December 31, 2017 3,336,060 $ 0.02 $ 0.02 2.88 November 19, 2020 $ 40,033 Issued - - - - - - Expired - - - - - - Exercised - - - - - - Balance outstanding and exercisable at December 31, 2018 3,336,060 $ 0.02 $ 0.02 1.88 November 19, 2020 $ 6,672 |